EP2164349B1 - Formule sans protéine - Google Patents

Formule sans protéine Download PDF

Info

Publication number
EP2164349B1
EP2164349B1 EP07766165.0A EP07766165A EP2164349B1 EP 2164349 B1 EP2164349 B1 EP 2164349B1 EP 07766165 A EP07766165 A EP 07766165A EP 2164349 B1 EP2164349 B1 EP 2164349B1
Authority
EP
European Patent Office
Prior art keywords
composition
carbohydrate
protein
total
digestible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07766165.0A
Other languages
German (de)
English (en)
Other versions
EP2164349A2 (fr
Inventor
Jane Elizabeth Langford
Ian Sullivan
Catherine Teresa Deering
Sandra Helen Giffen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHS International Ltd
Original Assignee
SHS International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38657076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2164349(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SHS International Ltd filed Critical SHS International Ltd
Priority to PL07766165T priority Critical patent/PL2164349T3/pl
Priority to EP14181628.0A priority patent/EP2845496A1/fr
Publication of EP2164349A2 publication Critical patent/EP2164349A2/fr
Application granted granted Critical
Publication of EP2164349B1 publication Critical patent/EP2164349B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
    • C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
    • C11C1/04—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by hydrolysis
    • C11C1/045—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by hydrolysis using enzymes or microorganisms, living or dead
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the stimulation of health in infants receiving an amino acid based formula.
  • infants are breastfed by the mother.
  • breastfeeding is stopped and the infant diet comprises mainly infant milk formula.
  • the infant food consists of hydrolysed milk proteins, amino acids or non-milk proteins e.g. soy proteins and other nutritional components which do not cause allergic reactions.
  • Neocate TM for use in patients suffering from allergy, gastro-intestinal complaints, eczema, malabsorption or maldigestion.
  • WO2005039319 discloses the use of synbiotics in infant formula including protein in hydrolysate form, thereby reducing the risk of allergy (page 11, line 35-37)
  • WO 2007/054989 describes anallergenic probiotic bacterial cultures.
  • WO2006091103 discloses a nutritional composition comprising synbiotics for the treatment and prevention of immune disorders including allergy. The use of protein hydrolysate and/or free amino acids for reducing the risk of allergy is disclosed.
  • the present inventors have recognized that in an elemental formula containing a variety of free amino acids without intact protein, it is highly unpredictable how the intestinal flora develops. Instead of the bifidobacteria and lactobacilli dominant flora in normal infants receiving breast milk, many other bacterial species, including potentially pathogenic species, may prevail in the intestine of infants receiving amino acid based foods.
  • the present inventors have recognized that the healthy flora development is of very high importance in infants receiving a diet containing mainly free amino acid as a protein source. Without being bound by theory, the inventors recognized that a good flora, i.e. a flora rich in Bifidobacteria and Lactobacilli, is especially beneficial for the maturation of the (mucosal) immune system. A good flora prevents the development of allergies or at least reduces the severity of the allergies in such infants. Hence the present inventors recognized the criticality of a beneficial flora development in these infants.
  • the prebiotic fibres according to this invention are carefully selected from the known prebiotic fibres in order to prevent the addition of milk or other intact and potential allergenic proteins that are present in the fibres to the non-allergic composition.
  • the inventors surprisingly found in an internationally recognised model for allergy, that when prebiotic fibres are combined with probiotic bacterial, namely Bifidobacteria, a synergistic effect was present on the prevention of allergic reactions. This synergistic effect is potentially very beneficial to the infants, but could also be beneficial to adults.
  • a preferred embodiment according to the invention comprises the use of a composition comprising free amino acids as a sole source of protein, a fatty acid source comprising long chain polyunsaturated fatty acids, a carbohydrate source comprising digestible and indigestible carbohydrates, and milk protein free Bifidobacteria for the manufacture of a composition for treating a person suffering from
  • sole source of protein means that present composition (preferably) contains at least 99 wt.% amino acids based on total protein, preferably at least 99.5, more preferably at least 99.9 wt.%.
  • composition comprising a protein component, a fat component, a digestible carbohydrate component, a non-digestible carbohydrate and milk protein free bifidobacteria wherein;
  • the nutritional composition comprises both the non digestible fibres and the Bifidobacteria since this composition gives the best results in the allergic mouse model. (see figure 1 ).
  • Bifidobacteria breve is used.
  • Fructans are fructose based neutral oligosaccharides (>50% of the monose units are fructose), preferably inulin, fructan and/or fructooligosaccharide, most preferably a mixture of long chain fructooligosaccharide (IcFOS) with an average DP between 10 - 60 and short chain fructooligosaccharide (scFOS) with an average DP between 3 and 10.
  • IcFOS long chain fructooligosaccharide
  • scFOS short chain fructooligosaccharide
  • Preferred embodiment comprises a mixture of IcFOS and scFOS in a ratio of 1:9 since this ratio comes closer to the composition of oligosaccharides in breast milk and has been proven to effectively stimulate the growth of bifidobacteria in infants.
  • the present method preferably comprises the administration of a serving comprising between 0.05 and 25 grams non-digestible saccharide, preferably between 0.1 and 5 grams.
  • the present method preferably comprises the administration of a serving comprising between 0.05 and 25 grams scFOS, preferably between 0.1 and 5 gram scFOS.
  • the present method preferably comprises the administration of 0.05 to 25 grams non-digestible saccharide per day, preferably between 0.1 and 5 grams per day.
  • Pectin is divided into two main categories: high methoxylated pectin, which is characterized by a degree of methoxylation above 50% and low methoxylated pectin having a degree of methoxylation below 50%.
  • degree of methoxylation also referred to as DE or “degree of esterification”
  • the present pectin is preferably prepared from high methoxylated pectin.
  • the pectin is preferably characterized by a degree of methoxylation above 20%, preferably above 30 % even more preferably above 50%.
  • the pectin as used in the present method has an average degree of polymerization (DP) between 2 and 500, preferably between 10 and 250 and most preferably between 20 and 50.
  • DP average degree of polymerization
  • the average DP of the acid oligosaccharide mixture is preferably between 3 and 1000, more preferably between 3 and 250, even more preferably between 3 and 50. It was found that a lower DP of the oligosaccharides improves the palatability and results in a reduced viscosity product if the acid oligosaccharide is administered in liquid form.
  • the pectin is preferably administered in an amount of between 0.1 and 100 gram per day, preferably between 0.4 and 50 grams per day, even more preferably between 1 and 20 gram per day.
  • a preferred embodiment comprises fructans and pectin degradation products in a ratio 50:50 - 95: 5.
  • the ratio is 85:15 since this is the ratio of neutral oligosaccharides and acidic oligosaccharides as present in mother's milk.
  • the probiotic bacteria that are suitable for use in the invention should preferably have at least a positive effect in the mouse allergy model as described in the examples below.
  • the probiotics further must be harvested in substantial absence of food allergens. This requires special procedures or culture media without intact proteins for the preparation of the probiotic bacteria.
  • the present invention requires probiotic bacteria in substantial absence of milk proteins.
  • the probiotic bacteria are bifidobacteria. Even more preferred the probiotic bacterium is Bifidobacterium breve. Bifidobacteria have the strongest tolerance inducing effect in the mouse models used and are therefore preferred. In particular Bifidobacterium breve is highly effective.
  • the Bifidobacteria are non-viable. This has the advantage that the shelf life of the product becomes longer and that the immune modulatory activity of the bacteria becomes independent of the number of live bifidobacteria. Experiments have shown that immune stimulatory effects of non-viable bacteria is similar and sometimes even better than the activity of live bifidobacteria.
  • the present composition preferably comprises 10 2 to 10 13 colony forming units (cfu) of bifidobacteria per gram dry weight of the present composition, preferably 10 2 to 10 12 cfu, more preferably 10 5 to 10 10 cfu, most preferably from 10 4 to 5x10 9 cfu.
  • Amino acids can be used in nutritional formula for babies and infants.
  • the composition of the amino acids in the formula preferably comprises all essential amino acids except for patients with phenylketonuria (PKU) and non-PKU inborn errors of metabolism, and is preferably optimal for baby food or infant nutrition.
  • PKU phenylketonuria
  • the inventors than found that the most optimal amino acid composition should be as close as possible to the amino acid composition of the protein fraction of mothers' milk. This results in a preferred amino acid composition as depicted in table 1 (see infra ).
  • the composition comprises less than 1 wt.% peptides based on total protein and more than 99 wt.% free amino acids based on total protein, comprising at least the following free amino acids: alanine, arginine, aspartic acid, cysteine, glycine, histidine, isoleucine, leucine, lysine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine and glutamine;
  • Formula according to the invention comprise free amino acids as nitrogen source, fat including a fat blend comprising LCPUFA and carbohydrates. Vitamins and minerals are added according to legislation requirements.
  • the present composition preferably provides nutrition to the infant, and comprises a lipid component, a protein component and a carbohydrate component.
  • the lipid component preferably provides 5 to 50% of the total calories
  • the protein component preferably provides 5 to 50% of the total calories
  • the carbohydrate component preferably provides 15 to 90% of the total calories.
  • the present composition is preferably used as an infant formula, wherein the lipid component provides 35 to 50% of the total calories, the protein component provides 7.5 to 12.5% of the total calories, and the carbohydrate component provides 40 to 55% of the total calories.
  • the total of energy provided by the amino acids needs to be taken.
  • the content of LC-PUFA with 20 and 22 carbon atoms in the present composition preferably does not exceed 15 wt.% of the total fat content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.% of the total fat content.
  • the present composition comprises at least 0.1 wt.%, preferably at least 0.25 wt, more preferably at least 0.5 wt.%, even more preferably at least 0.75 wt.% LC-PUFA with 20 and 22 carbon atoms of the total fat content.
  • the Docosahexaenoic acid (DHA) content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, but is at least 0.1 wt% of the total fat.
  • the present composition comprises relatively high amounts, preferably at least 0.1 wt.%, even more preferably at least 0.25 wt.%, most preferably at least 0.5 wt.% of the total fat.
  • the AA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.% of the total fat. Excess metabolites from AA may cause inflammation.
  • the present composition preferably comprises AA and DHA, wherein the weight ratio AA/DHA preferably is above 0.25, preferably above 0.5, even more preferably above 1. The ratio is preferably below 25.
  • the LC-PUFAs are preferably non-fish derived single cell oils, e.g. available from Martek.
  • compositions in accordance with the invention are set out in Tables 1-3.
  • Table 1 Amino acid content of composition according to the invention AA content as percentage of total AA Amino Acid Units Range (g/100g) Infant 0 -1 year Infant 1-10 year Ala gm 3.95 4.01 3.12 3.03 Arg gm 6.99 7.02 14.24 13.91 Asp gm 6.54 6.57 5.73 5.59 Cys gm 2.59 2.58 1.85 2.91 Glu acid gm 0.00 0.00 0.00 Gly gm 6.15 6.12 5.11 5.01 His gm 4.02 3.99 3.71 3.61 Iso gm 6.15 6.12 5.11 5.01 Leu gm 10.56 10.51 8.54 8.32 Lys gm 7.19 7.19 6.25 6.11 Meth gm 1.68 1.69 4.02 3.90 Phe gm 7.51 7.47 7.10 6.93 Pro gm 4.73 4.72 5.97 5.82 Ser gm 4.60 4.61 3.71 3.61 thr gm 5.18 5.17
  • Nutritional infant formula for allergic infants Nutritional Profile of formula for infants according to the invention (powder) Units Level/100g Level/100kcal Protein Equivalent gm 13 2.9 Energy kcals 455 100 Nitrogen gm 2.1 Carbohydrate gm 49 10.8 Fat (total) gm 23 5.1 (MCT) % 33 (LCT) % 67 Table 3. Ranges in Long Chain Polyunsaturated (LCP) fatty acid composition % Fatty acids Preferred Range +/-25% Arachidonic acid 0.35 0.26 0.44 Docosahexanoic acid 0.20 0.15 0.25 Total LCP 0.55 0.41 0.69
  • the preferred ranges in the oligosaccharide composition are 0.4-1.2g/100ml wherein 85 w% is scFOS and IcFOS and 15 w% is pectin hydrolysate.
  • the ratio scFOS to IcFOS is between 2 and 20 even more preferably the ratio is 9.
  • One preferred embodiment of milk protein and allergen free, nutritionally complete powdered formulation in accordance with the invention which is suitable for dilution with water to form an enteral feed comprises: Component Per 100g Powder Protein equivalent (g) 13 Total amino acids (g) 15.5 Total fat (g) 23 Sunflower oil (g) 4 Fractionated coconut oil (g) 7 Canola oil (g) 4 High oleic sunflower oil (g) 6.6 ARASCO TM oil (g) 0 . 21 DHASCO TM oil (g) 0 . 11 Carbohydrate: Maltodextrin (g) 49 Prebiotic (g) 5.33 ScFOS (g) 4 . 1 IcFOS (g) 0.43 AOS ( g ) 0.8 Probiotic: B Breve (colony forming units; CFU) 1 x 10 10 Other vitamins/minerals/trace elements Balance
  • the above formulation provides approximately 455 kcal of energy per 100g powder.
  • the formulation may be diluted with cooled, boiled water to provide a recommended concentration of 15% w/v.
  • composition is used for treating an infant (particularly with an atopic constitution) suffering from
  • the composition can also preferably be used to improve the stool characteristics of infants suffering from the above mentioned symptoms.
  • the composition is specifically designed for infants between 0-and 3 years. With some adaptations in the amino acid profile (see table 1) the composition is also suitable for infants between 3 and 10 years old. Allergic infants often suffer from diarrhoea but constipation also occurs.
  • a preferred composition can be used to prevent and treat these symptoms comprises fibres according to the composition of mothers milk, wherein the ratio scFOS/lcFOS is 9:1 and additionally pectin hydrolysate is present.
  • mice Female 6- and 8-week old C57BI/6JOIaHsd mice were obtained from Harlan (Horst, the Netherlands) and kept under normal conditions with a 12 h dark and light cycle and free access to food and water. All experiments were approved by an independent animal experiments committee (DEC Consult, Bilthoven, The Netherlands).
  • Vaccination experiments were performed using Influvac (Solvay Pharmaceuticals, Weesp, the Netherlands) from season 2002/2003. It is an inactivated influenza virus vaccine based on isolated haemagglutinin (HA) and neuraminidase antigens of three strains of myxovirus influenza, in a dose equivalent to 30 ⁇ g/mL HA per strain (90 ⁇ g/mL HA in total). An oil-adjuvant was used in all vaccinations (Stimune, previously known as Specol; Cedi-diagnostics, Lelystad, The Netherlands).
  • mice received a primary vaccination and a booster vaccination, consisting of a subcutaneous (sc) injection of a 1:1 mix of vaccine and adjuvant in a total volume of 100 ⁇ L.
  • the booster vaccination was given 21 days after the primary vaccination.
  • the experiments ended 10 days after booster vaccination.
  • Blood samples were taken before primary and secondary vaccination and at the end of the experiment.
  • Negative control groups that were included in all experiments (indicated with 'sham group') received injections with a 1:1 mix of PBS and adjuvant in a total volume of 100 ⁇ L. Sham groups were never used for statistical comparisons to supplemented groups, but served solely to demonstrate the specificity of vaccine-induced responses.
  • DTH reactions were induced 9 days after booster vaccination, by sc injection of 25 ⁇ L Influvac into the ear pinnae of both ears. Ear thickness was measured in duplicate before vaccine challenge and 24 h thereafter, using a digital micrometer (Mitutoyo Digimatic 293561, Veenendaal, The Netherlands). The DTH response was calculated by subtracting the basal ear thickness from the value at 24 h after challenge.
  • Casein and whey are obtained from DMV international, Veghel, The Netherlands. Cholera toxin is purchased from Quadratech Diagnostics, Epsom, UK. PBS is purchased from Cambrex Bio Science, Verviers, Belgium. Elisa coating buffer is obtained from Sigma, Alphen aan den Rijn, The Netherlands. Biotin labeled rat anti mouse IgE is purchased from BD Biosciences, Alphen aan den Rijn, The Netherlands. All other chemicals are obtained from Sigma-Aldrich-Chemie, Zwijndrecht, The Netherlands.
  • CT cholera toxin
  • the acute allergen specific skin response was measured after injection of the specific protein in the ear pinnae.
  • the control, casein sensitized mice were injected intra dermal (i.d.) in the left ear with 20 ⁇ L homogenized casein (0.5 mg/mL in PBS) respectively.
  • the right ear 20 ⁇ L PBS was injected as a vehicle control.
  • the CT and PBS mice received a casein ear challenge using PBS injections as control.
  • Ear thickness was measured in duplicate using a digital micrometer (Mitutoyo, Veenendaal, The Netherlands), at 0, 1, 4 and 24 hour after challenge.
  • the allergen specific ear swelling was calculated by subtracting the basal (0 h) and the control (right ear) thickness from the value measured at the three different time points (1, 4 and 24 h).
  • Concentrations of total IgE and levels casein or whey specific IgE, IgG1 and IgG2a were determined in serum of sacrificed mice by means of ELISA.
  • Microlon plates (Greiner, Alphen aan den Rijn, The Netherlands) were coated with casein in coating buffer or rat anti-mouse IgE (1 ⁇ g/mL) in PBS for 18 hours at 4°C. Plates were washed and blocked for 1 hour with 5% BSA. Serum samples were applied in several dilutions and incubated for 2 hours at room temperature. Plates were washed 5 times and incubated with 1 ⁇ g biotin labeled rat anti mouse IgE for one and a half hour at room temperature.
  • HRP horse radish peroxidase
  • OPD o-phenylendiamine
  • TD1 Bifidobacterium breve
  • Fig 2 The results of the mouse casein allergy model are shown in Fig 2 and demonstrates that the combination of dietary fiber and TD1 synergistically inhibits the "allergenic" DTH response to casein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pediatric Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (16)

  1. Utilisation d'une composition comprenant plus de 99 % en pds d'acides aminés libres sur la base de la protéine totale, une source d'acides gras comprenant des acides gras polyinsaturés à longue chaîne, une source d'hydrates de carbone comprenant des hydrates de carbone digestibles et non digestibles, et des bifidobactéries exemptes de protéine de lait pour la fabrication d'une composition pour le traitement d'une personne souffrant de
    a. colique, congestion, hydrorrhée nasale, respiration sifflante, vomissement, diarrhées, selles sanguinolentes, mucus dans les selles, rash, eczéma, reflux gastro-oesophagien, oesophagite éosinophile ou d'asthme ;
    b. d'allergie au lait de vache et/ou d'intolérance aux protéines alimentaires ; et/ou
    c. d'infections,
    dans laquelle l'hydrate de carbone non digestible est sélectionné parmi une source exempte de protéine de lait et la composition totale est essentiellement exempte de protéines intactes.
  2. Utilisation selon la revendication 1 dans laquelle la personne est un nourrisson d'un âge compris entre 0 et 36 mois.
  3. Utilisation d'une composition comprenant des acides aminés libres comme unique source d'acides aminés, une source d'acides gras comprenant des acides gras polyinsaturés à longue chaîne, une source d'hydrates de carbone comprenant des hydrates de carbone digestibles et non digestibles, et des bifidobactéries exemptes de protéine de lait pour la fabrication d'une composition de stimulation de la maturation du système immunitaire chez un nourrisson présentant une constitution atopique, dans laquelle l'hydrate de carbone non digestible est sélectionné parmi une source exempte de protéine de lait et la composition totale est essentiellement exempte de protéines intactes.
  4. Utilisation selon l'une quelconque des revendications 1 à 3 dans laquelle les acides aminés libres sur la base de la protéine totale, comprenant au moins les acides aminés libres suivants : alanine, arginine, acide aspartique, cystéine, glycine, histidine, isoleucine, leucine, lysine, méthionine, proline, sérine, thréonine, tryptophane, tyrosine, valine et glutamine.
  5. Utilisation d'une composition selon l'une quelconque des revendications 1 à 4 dans laquelle les acides aminés comprennent entre 5 - 16 % en énergie de la composition totale, entre 30 - 60 % en énergie de matière grasse, dont entre 0,1 - 5 % en énergie d'AGPLC et entre 25 - 75 % en énergie d'hydrates de carbone digestibles.
  6. Utilisation selon la revendication 5 dans laquelle l'AGPLC représente entre 0,2 - 1 % en énergie de la composition totale.
  7. Utilisation selon l'une quelconque des revendications 1 à 6 dans laquelle l'hydrate de carbone non digestible comprend (i) du fructane soluble avec un degré moyen de polymérisation compris entre 3 et 200 et (ii) un acide galacturonique soluble avec un degré moyen de polymérisation compris entre 3 et 200.
  8. Composition comprenant un composant protéique, un composant gras, un composant hydrate de carbone digestible, un hydrate de carbone non digestible et des bifidobactéries exemptes de protéine de lait dans laquelle :
    (a) le composant protéique comprend plus de 99 % en pds d'acides aminés libres sur la base de la protéine totale et comprend au moins les acides aminés libres suivants : alanine, arginine, acide aspartique, cystéine, glycine, histidine, isoleucine, leucine, lysine, méthionine, proline, sérine, thréonine, tryptophane, tyrosine, valine et glutamine ;
    (b) le composant hydrate de carbone digestible contient moins de 2 % en pds de lactose sur la base de l'hydrate de carbone digestible total ;
    (c) l'hydrate de carbone non digestible comprend du fructane soluble avec un DP moyen compris entre 2 et 200 et un acide galacturonique soluble avec un DP moyen compris entre 2 et 200 ; et
    (d) le composant gras comprend entre 0,1 et 5 % en pds d'AGPLC sur la base de la teneur totale en acides gras.
  9. Composition selon la revendication 8 dans laquelle :
    le composant gras comprend entre 0,2 et 1 % en pds d'AGPLC sur la base de la teneur totale en acide gras.
  10. Composition selon la revendication 8 ou 9, comprenant du fructane soluble non digestible avec un DP moyen compris entre 2 à 200 et un acide galacturonique soluble non digestible avec un DP moyen compris entre 2 et 200.
  11. Composition selon l'une quelconque des revendications 8 à 10, comprenant Bifidobacterium breve.
  12. Composition selon l'une quelconque des revendications 8 à 11, comprenant de l'acide arachidonique et/ou de l'acide docosahexaénoïque.
  13. Composition selon l'une quelconque des revendications 8 à 12, dans laquelle l'hydrate de carbone non digestible est constitué de FOS à longue chaîne et de FOS à chaîne courte.
  14. Composition selon la revendication 13 dans laquelle le FOS à longue chaîne a un DP moyen compris entre 10 - 60 et le FOS à chaîne courte a un DP moyen compris entre 3 et 10.
  15. Composition selon l'une quelconque des revendications 8 à 14 dans laquelle le produit est une poudre ou un liquide.
  16. Composition comprenant des acides aminés libres comme unique source de protéine, une source d'acide gras comprenant des acides gras polyinsaturés à longue chaîne, une source d'hydrates de carbone comprenant des hydrates de carbone digestibles et non digestibles, et des bifidobactéries exemptes de protéine de lait dans laquelle l'hydrate de carbone non digestible est sélectionné parmi une source exempte de protéine de lait et la composition totale est essentiellement exempte de protéines intactes pour l'utilisation dans le traitement d'une personne souffrant de
    (a) colique, congestion, d'hydrorrhée nasale, respiration sifflante, vomissement, diarrhées, selles sanguinolentes, mucus dans les selles, rash, eczéma, reflux gastro-oesophagien, oesophagite éosinophile ou d'asthme ;
    (b) d'allergie au lait de vache et/ou d'intolérance aux protéines alimentaires ;
    (c) et/ou d'infections.
EP07766165.0A 2006-08-04 2007-07-05 Formule sans protéine Active EP2164349B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL07766165T PL2164349T3 (pl) 2006-08-04 2007-07-05 Bezproteinowa mieszanka dla niemowląt
EP14181628.0A EP2845496A1 (fr) 2006-08-04 2007-07-05 Formule alimentaire sans protéine comprenant des prébiotiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82146106P 2006-08-04 2006-08-04
PCT/GB2007/002520 WO2008015374A2 (fr) 2006-08-04 2007-07-05 Formule sans protéine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP14181628.0A Division EP2845496A1 (fr) 2006-08-04 2007-07-05 Formule alimentaire sans protéine comprenant des prébiotiques

Publications (2)

Publication Number Publication Date
EP2164349A2 EP2164349A2 (fr) 2010-03-24
EP2164349B1 true EP2164349B1 (fr) 2014-09-10

Family

ID=38657076

Family Applications (4)

Application Number Title Priority Date Filing Date
EP07766165.0A Active EP2164349B1 (fr) 2006-08-04 2007-07-05 Formule sans protéine
EP14181628.0A Ceased EP2845496A1 (fr) 2006-08-04 2007-07-05 Formule alimentaire sans protéine comprenant des prébiotiques
EP16177232.2A Revoked EP3114943B1 (fr) 2006-08-04 2007-08-03 Produit alimentaire non allergénique
EP07808526.3A Active EP2061346B1 (fr) 2006-08-04 2007-08-03 Composition alimentaire pour la réduction de la sensibilité à un allergène

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP14181628.0A Ceased EP2845496A1 (fr) 2006-08-04 2007-07-05 Formule alimentaire sans protéine comprenant des prébiotiques
EP16177232.2A Revoked EP3114943B1 (fr) 2006-08-04 2007-08-03 Produit alimentaire non allergénique
EP07808526.3A Active EP2061346B1 (fr) 2006-08-04 2007-08-03 Composition alimentaire pour la réduction de la sensibilité à un allergène

Country Status (15)

Country Link
US (5) US8691213B2 (fr)
EP (4) EP2164349B1 (fr)
KR (1) KR20090045930A (fr)
CN (3) CN101795579A (fr)
AU (2) AU2007280272A1 (fr)
BR (2) BRPI0721827B8 (fr)
DK (2) DK2164349T3 (fr)
ES (2) ES2525223T3 (fr)
IL (1) IL196786A0 (fr)
MX (1) MX2010000172A (fr)
PL (2) PL2164349T3 (fr)
PT (2) PT2164349E (fr)
RU (1) RU2436414C2 (fr)
WO (2) WO2008015374A2 (fr)
ZA (1) ZA200900817B (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
EP2164349B1 (fr) 2006-08-04 2014-09-10 SHS International Ltd. Formule sans protéine
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009058799A1 (fr) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions et procédés de prévention et de traitement de maladies touchant des mammifères
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
GB0805360D0 (en) * 2008-03-25 2008-04-30 Univ Leuven Kath Arabinoxylan oligosaccharide preparation
EP2143340A1 (fr) * 2008-07-07 2010-01-13 Nestec S.A. Composition nutritionnelle comprenant des acides aminés libres et des lipides structurés
GB2480042B (en) 2009-02-24 2014-03-12 Ritter Pharmaceuticals Inc Solid oral unit-dosage prebiotic forms and methods of use
US9364538B2 (en) * 2009-08-18 2016-06-14 Cosucra-Groupe Warcoing Sa Compositions containing mixtures of fermentable fibers
WO2011021926A1 (fr) 2009-08-21 2011-02-24 N.V. Nutricia Régulation de l'ensemble d'acides aminés utilisé pour la synthèse de protéine en phase aiguë
PL2332428T3 (pl) * 2009-12-04 2015-02-27 Mjn Us Holdings Llc Formulacja odżywcza zawierająca hydrolizat zawierający peptydy mleka krowiego i/lub pochodzące z niego peptydy do indukowania tolerancji
EP3202406A1 (fr) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Formulations prébiotiques et méthodes d'utilisation
WO2011149335A1 (fr) * 2010-05-25 2011-12-01 N.V. Nutricia Composition nutritionnelle d'empreinte immunitaire
EP2575508B1 (fr) * 2010-06-04 2019-01-09 N.V. Nutricia Oligosaccharides non digestibles pour induire la tolerance alimentaire de proteines diététiques
WO2011150949A1 (fr) * 2010-06-04 2011-12-08 N.V. Nutricia Oligosaccharides non digestibles pour l'induction d'une tolérance orale contre des protéines alimentaires
BR112013000566A2 (pt) * 2010-07-11 2016-07-05 Univ Arkansas composições e métodos para o aumento da capacidade de eclosão de aves e prévio desempenho
CN101940238B (zh) * 2010-08-13 2013-09-11 广东润科生物工程有限公司 一种营养保健食用油及其制备方法和其包装结构
CN101978841B (zh) * 2010-08-31 2013-04-10 浙江贝因美科工贸股份有限公司 一种抗蛋白过敏及营养婴儿配方奶粉
EP3494969B1 (fr) 2010-09-24 2024-03-13 University of Florida Research Foundation, Inc. Composition thérapeutique stérile formulée pour une administration entérale comprenant un ou plusieurs acides aminés destinée à être utilisée pour restaurer ou améliorer la fonction de barrière de l'intestin grêle d'un patient présentant une lésion de la muqueuse de l'intestin grêle
EP2465508A1 (fr) * 2010-11-23 2012-06-20 Nestec S.A. Composition comportant des protéines hydrolysées et oligosaccharides pour le traitement des maladies de la peau
PH12013501360A1 (en) 2010-12-29 2021-08-09 Abbott Lab Nutritional products including a novel fat system including monoglycerides
CN108741083A (zh) 2010-12-31 2018-11-06 雅培制药有限公司 促进有益细菌生长的中性人乳寡糖
US9283240B2 (en) 2010-12-31 2016-03-15 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
CN109620834A (zh) 2010-12-31 2019-04-16 雅培制药有限公司 使用人乳寡糖改善呼吸道健康的方法
MY192208A (en) 2010-12-31 2022-08-08 Abbott Lab Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
CA2822219C (fr) 2010-12-31 2020-12-29 Abbott Laboratories Methodes visant a diminuer la frequence de l'enterocolite necrosante chez les nourrissons, les jeunes enfants ou les enfants a l'aide d'oligosaccharides du lait humain
CN107510040A (zh) 2010-12-31 2017-12-26 雅培制药有限公司 包含人乳低聚糖和核苷酸的营养型组合物以及其治疗和/或预防肠病毒感染的用途
BR112013016606A2 (pt) 2010-12-31 2016-09-27 Abbott Lab processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
MX368124B (es) 2011-08-29 2019-09-19 Abbott Lab Oligosacaridos de leche humana para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
US20140303067A1 (en) * 2011-10-06 2014-10-09 N.V. Nutricia Treatment of eosinophilic esophagitis
WO2013133691A1 (fr) * 2012-03-09 2013-09-12 N.V. Nutricia Composition nutritionnelle liquide comprenant des acides aminés libres
ES2795104T3 (es) 2012-09-21 2020-11-20 Nestle Sa Fenoles vegetales y su uso en el tratamiento o la prevención de la esofagitis eosinofílica
ES2884223T3 (es) * 2012-11-02 2021-12-10 Nutricia Nv Combinación de simbióticos para la mejora del cerebro
CA2904046C (fr) * 2013-03-11 2020-01-14 University Of Florida Research Foundation, Incorporated Matieres et procedes pour ameliorer une fonction pulmonaire et pour prevenir et/ou traiter des complications pulmonaires induites par rayonnement
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
WO2014200334A1 (fr) * 2013-06-14 2014-12-18 N.V. Nutricia Composition synbiotique pour le traitement d'infections chez des patients allergiques
WO2015154259A1 (fr) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Compositions nutritionnelles de synthèse sexospécifiques et systèmes nutritionnels les comprenant
WO2015154251A1 (fr) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Compositions nutritionnelles de synthèse sexospécifiques et systèmes nutritionnels les comprenant
WO2015154254A1 (fr) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Compositions nutritionnelles de synthèse sexospécifiques et systèmes nutritionnels les comprenant
WO2015154257A1 (fr) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Compositions nutritionnelles de synthèse sexospécifiques et systèmes nutritionnels les comprenant
WO2016148562A1 (fr) * 2015-03-18 2016-09-22 N.V. Nutricia Procédé pour induire une tolérance orale par administration d'un peptide dérivé de bêta-lactoglobuline en combinaison avec un probiotique
EP3294308A4 (fr) 2015-05-14 2019-03-06 University of Puerto Rico Procédé de restauration du microbiote de nouveau-nés
CN108348493B (zh) * 2015-10-02 2022-03-29 荷兰纽迪希亚公司 甘氨酸用于过敏性患者的耐受性诱导
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX2018006540A (es) * 2015-12-04 2018-08-15 Nestec Sa Polifenoles de cacao y fibra dietetica soluble para usar en el tratamiento o la prevencion de trastornos asociados con una cantidad por encima de lo normal de granulocitos en un tejido.
EP3397075A1 (fr) * 2015-12-29 2018-11-07 N.V. Nutricia Formule nutritionnelle à base d'oligosaccharides non digestibles et de bactéries non réplicatives produisant de l'acide lactique
CN107041546A (zh) * 2016-02-05 2017-08-15 上海他普亚贸易有限公司 一种氨基酸配方粉及其制备方法
CA2973679A1 (fr) * 2016-07-15 2018-01-15 Kay Jay, Llc Composition et methode de modification de la pigmentation des cheveux
EP3522882A4 (fr) * 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated Compositions d'acides aminés et utilisations associées
AU2019310346A1 (en) * 2018-07-24 2021-01-28 Clover Corporation Limited Protein encapsulation of nutritional and pharmaceutical compositions
CN112244097A (zh) * 2020-10-19 2021-01-22 湖南欧比佳营养食品有限公司 一种含有氨基酸及无乳糖的配方奶粉及其制备方法
US20240009216A1 (en) 2020-11-10 2024-01-11 Societe Des Produits Nestle S.A. Nutritional composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH636248A5 (fr) * 1979-03-09 1983-05-31 Nestle Sa Procede de preparation d'un hydrolysat de proteines purifie.
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
US6077558A (en) * 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6511696B2 (en) * 2000-12-13 2003-01-28 Novartis Nutrition Ag Infant formula with free amino acids and nucleotides
DE10221403A1 (de) 2002-05-14 2003-12-04 Kyberg Pharma Vertriebs Gmbh & Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung
ATE429232T1 (de) 2003-10-24 2009-05-15 Nutricia Nv Immunmodulierende oligosaccharide
CA2543626C (fr) 2003-10-24 2013-08-27 N.V. Nutricia Composition symbiotique pour nourrissons
EP1597978A1 (fr) * 2004-05-17 2005-11-23 Nutricia N.V. Synergie de GOS et polyfructose
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1634599A1 (fr) 2004-08-20 2006-03-15 N.V. Nutricia Aliment infantile à activité immunostimulatrice
RU2282995C2 (ru) 2004-12-17 2006-09-10 Открытое акционерное общество "Лианозовский молочный комбинат" Пищевой продукт
TW200637908A (en) 2005-01-04 2006-11-01 Calpis Co Ltd Method for preparation of lactic acid bacterium having anti-allergic activity
WO2006091103A2 (fr) * 2005-02-28 2006-08-31 N.V. Nutricia Composition nutritive contenant des probiotiques
EP1714660A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia D'acide uronique et des probiotiques
WO2007054969A2 (fr) 2005-09-21 2007-05-18 Torrent Pharmaceuticals Limited Procede atypique de preparation de lercanidipine
SI2169050T1 (sl) * 2005-10-11 2014-06-30 Probiotical S.P.A. Postopek za pripravo nealergijskih probiotičnih bakterijskih kultur in njihova uporaba
US20070114476A1 (en) * 2005-11-04 2007-05-24 Williams Christopher P Low radiocarbon nucleotide and amino acid dietary supplements
EP2164349B1 (fr) 2006-08-04 2014-09-10 SHS International Ltd. Formule sans protéine

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Also Published As

Publication number Publication date
WO2008015374A2 (fr) 2008-02-07
BRPI0721827B1 (pt) 2020-11-17
CN104012838B (zh) 2017-09-19
IL196786A0 (en) 2009-11-18
RU2009107681A (ru) 2010-09-10
CN101522055A (zh) 2009-09-02
EP2061346B1 (fr) 2016-09-07
US20100172876A1 (en) 2010-07-08
CN104012838A (zh) 2014-09-03
WO2008016306A1 (fr) 2008-02-07
PT2164349E (pt) 2014-12-11
BRPI0721827B8 (pt) 2021-05-25
PT2061346T (pt) 2016-12-15
EP3114943A1 (fr) 2017-01-11
BRPI0721827A2 (pt) 2013-05-21
US20090181154A1 (en) 2009-07-16
EP2164349A2 (fr) 2010-03-24
EP2061346A1 (fr) 2009-05-27
US20140193542A1 (en) 2014-07-10
US20160338398A1 (en) 2016-11-24
MX2010000172A (es) 2012-09-25
EP3114943B1 (fr) 2019-02-27
ZA200900817B (en) 2009-12-30
ES2525223T3 (es) 2014-12-19
AU2007280272A2 (en) 2010-07-22
PL2164349T3 (pl) 2015-03-31
US9427011B2 (en) 2016-08-30
PL2061346T3 (pl) 2017-03-31
KR20090045930A (ko) 2009-05-08
US8691213B2 (en) 2014-04-08
DK2164349T3 (en) 2014-12-15
ES2605177T3 (es) 2017-03-13
US20080031814A1 (en) 2008-02-07
RU2436414C2 (ru) 2011-12-20
WO2008015374A3 (fr) 2008-04-24
AU2007280272A1 (en) 2008-02-07
BRPI0715335A2 (pt) 2013-07-09
AU2007279448A1 (en) 2008-02-07
EP2845496A1 (fr) 2015-03-11
CN101522055B (zh) 2014-03-19
DK2061346T3 (da) 2017-01-02
CN101795579A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
EP2164349B1 (fr) Formule sans protéine
CN101678053B (zh) 用于治疗或预防全身性炎症的方法
RU2552039C2 (ru) Способы и липидные композиции для содействия развитию кишечной флоры
RU2489888C2 (ru) Предотвращение аллергии при отлучении ребенка от груди
RU2600877C2 (ru) Ферментированное детское питание
CN101594789A (zh) 益生菌（婴儿）食品
TWI629994B (zh) 包括乳鐵蛋白之營養組成物於刺激免疫細胞上之用途
TWI639438B (zh) 乳糜瀉和食物過敏之膳食管理
CN112203531A (zh) 完整豌豆蛋白基营养组合物
MX2014004061A (es) Composiciones nutricionales de suero-caseina parcialmente hidrolizadas para reducir la aparicion de alergias.
TW201729693A (zh) 含有膳食性丁酸鹽之營養組成物和彼之用途
JP2012527224A (ja) オピオイド受容体刺激化合物（チモキノン、ニゲラ・サティバ）及び食物アレルギー
RU2721257C2 (ru) Питательные композиции и детские смеси, содержащие олигофруктозу, для снижения нагрузки патогенных бактерий в кишечнике младенцев и детей младшего возраста
EP2520181A1 (fr) Formulation fermentée pour nourrissons
Pannerchelvan et al. Functional yogurt: a comprehensive review of its nutritional composition and health benefits
WO2012078030A1 (fr) Formule fermentée pour nourrisson
RU2441399C2 (ru) Свободное от белка детское питание
CN119184309A (zh) 含深度水解酪蛋白的营养组合物及其食品和用途
CN114867368A (zh) 用于提高免疫适宜的营养组合物
CN118235853A (zh) 深度水解的婴儿配方食品
CN117693295A (zh) 用于肠道屏障功能的营养组合物
CHIOFALO Donkey milk: a new functional food
TW201233331A (en) Nutritional products including monoglycerides and fatty acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17P Request for examination filed (corrected)

Effective date: 20091223

17Q First examination report despatched

Effective date: 20120201

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140402

INTG Intention to grant announced

Effective date: 20140411

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 686213

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141015

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007038500

Country of ref document: DE

Effective date: 20141023

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20141201

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MARKS AND CLERK (LUXEMBOURG) LLP, CH

Ref country code: DK

Ref legal event code: T3

Effective date: 20141211

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2525223

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20141219

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141211

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150110

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007038500

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150705

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140910

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070705

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240611

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240530

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240613

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240611

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240604

Year of fee payment: 18

Ref country code: PT

Payment date: 20240626

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240529

Year of fee payment: 18

Ref country code: BE

Payment date: 20240617

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240612

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240529

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240712

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240801

Year of fee payment: 18

Ref country code: ES

Payment date: 20240805

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240625

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240701

Year of fee payment: 18